Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dutasteride may help prevent enteric neuronal damage in an animal model of Parkinson's disease, highlighting its potential for drug repurposing to address neuroinflammation.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

Ritlecitinib works well and is safe for treating alopecia areata.

In this case study of a 64-year-old woman with kerion celsi caused by Microsporum canis, treatment with the oral antifungal fosravuconazole resulted in symptom resolution without scarring or side effects over 12 weeks, suggesting its potential effectiveness for various dermatomycoses.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.

In a neonatal rat model, this study found that topical CDK2 inhibitors reduced chemotherapy-induced hair loss in 33 to 50% of the animals, suggesting a potential strategy for preventing alopecia in cancer patients.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This study reports no known changes in hair pigmentation associated with brentuximab vedotin, despite its various other documented adverse effects.

This study highlights that prolonged voriconazole use is linked to an increased risk of aggressive cutaneous malignancies like squamous cell carcinoma, necessitating careful monitoring of drug levels to manage adverse effects.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This study found that invasomes enhanced the iontophoretic transdermal delivery of finasteride in rabbits, increasing AUC and T1/2 compared to oral suspension.

In this study, combining thalidomide with CHOP treatment showed a significantly higher effective rate in treating peripheral T-cell lymphoma compared to CHOP alone, while both regimens were associated with similar levels of adverse reactions.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This case report describes a rare instance of renal cell carcinoma metastasizing to the ovary and early onset of alopecia after beginning sunitinib treatment, though hypothyroidism and dandruff complicate attribution to the drug.

This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.

In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.

This study observed that pantethine, a vitamin B5 precursor, attenuates tumor growth in immunocompetent mice by enhancing antitumor immunity, but its effect is limited by immune cell exhaustion over time.

This study found that a single injection of Platelet Rich Stroma improved knee function and reduced pain and stiffness in patients with knee osteoarthritis over twelve months.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.